Description:

Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Keywords:
Versions (1) ▾
  1. 4/1/21
Copyright Holder:
GlaxoSmithKline
Uploaded on:

April 1, 2021

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758

Long-Term Follow-Up for Survival and Disease Status; Patient Withdrawal from Study; Notification of Patient Death; Clarification Form

Administrative
Long-Term Follow-Up for Survival and Disease Status
Patient status
How was contact made?
Does the patient have an ongoing response to Iodine-131 Anti-B1 Antibody?
Has additional therapy been given for NHL since Anti-B1?
Has the patient had a documented new diagnosis of myelodysplasia?
Has the patient had a new diagnosis of another malignancy?
Is the patient taking thyroid medication?
Patient Withdrawal from Study
Reason for withdrawal from study
Notification of Patient Death
Cause of death
Relationship of study drug to patient's death
Source of information concerning death of patient
Clarification Form

Similar models